Table 2.

Comparison of baseline characteristics and outcomes in the randomized controlled trial and observational study of estrogen-progestin treatment in the Women’s Health Initiative (1994–2002).

	Clinical Trial		Observational Study
	Placebo Control	Estrogen-Progestin	Control	Estrogen-Progestin
Baseline Characteristics
White Race	83.9%	84.0%	82.3%	89.2%
Obese	34.0%	34.2%	27.3%	15.7%
College Degree or Higher	35.3%	34.5%	42.9%	53.4%
Current Smoker	10.5%	10.4%	7.0%	4.7%
Outcomes*
Coronary Heart Disease	0.33	0.40	0.28	0.20
Stroke	0.24	0.32	0.22	0.17
Venous Thromboembolism	0.17	0.35	0.16	0.17
Outcomes	Adjusted HR†, 95% CI		Adjusted HR, 95% CI
Coronary Heart Disease	1.27 (1.00–1.61)		0.87 (0.72–1.05)
Stroke	1.21 (0.93–1.59)		0.86 (0.70–1.07)
Venous Thromboembolism	2.13 (1.59–2.85)		1.31 (1.07–1.61)

^*Age-adjusted annualized incidence (%)

^†Adjusted for age, race, education, BMI, smoking, age at menopause, and physical functioning